BR112018076126A2 - compostos heterocíclicos como antibacterianos - Google Patents

compostos heterocíclicos como antibacterianos

Info

Publication number
BR112018076126A2
BR112018076126A2 BR112018076126-5A BR112018076126A BR112018076126A2 BR 112018076126 A2 BR112018076126 A2 BR 112018076126A2 BR 112018076126 A BR112018076126 A BR 112018076126A BR 112018076126 A2 BR112018076126 A2 BR 112018076126A2
Authority
BR
Brazil
Prior art keywords
antibacterials
heterocyclic compounds
compounds
tuberculosis
medicaments
Prior art date
Application number
BR112018076126-5A
Other languages
English (en)
Inventor
Émile Georges Guillemont Jérôme
Jean-Marie Bernard Raboisson Pierre
Tahri Abdellah
Original Assignee
Janssen Sciences Ireland Unlimited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Company filed Critical Janssen Sciences Ireland Unlimited Company
Publication of BR112018076126A2 publication Critical patent/BR112018076126A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

a presente invenção refere-se aos seguintes compostos, em que os números inteiros são como definidos na descrição e onde os compostos podem ser úteis como medicamentos, por exemplo, para uso no tratamento da tuberculose.
BR112018076126-5A 2016-06-16 2017-06-15 compostos heterocíclicos como antibacterianos BR112018076126A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16174719.1 2016-06-16
EP16174719 2016-06-16
PCT/EP2017/064652 WO2017216281A1 (en) 2016-06-16 2017-06-15 Heterocyclic compounds as antibacterials

Publications (1)

Publication Number Publication Date
BR112018076126A2 true BR112018076126A2 (pt) 2019-03-26

Family

ID=56132837

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018076126-5A BR112018076126A2 (pt) 2016-06-16 2017-06-15 compostos heterocíclicos como antibacterianos

Country Status (12)

Country Link
US (1) US11179396B2 (pt)
EP (1) EP3472158A1 (pt)
JP (1) JP2019518046A (pt)
KR (1) KR20190017948A (pt)
CN (1) CN109476657A (pt)
AU (1) AU2017286368B2 (pt)
BR (1) BR112018076126A2 (pt)
CA (1) CA3026010A1 (pt)
EA (1) EA201990043A1 (pt)
MA (1) MA45377A (pt)
MX (1) MX2018015656A (pt)
WO (1) WO2017216281A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3316969B1 (en) 2015-07-02 2022-03-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
IL257743B (en) 2015-09-17 2022-08-01 Marvin J Miller Heterocyclic compounds containing benzyl amine and preparations useful against mycobacterial inflammation
EP3472158A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
KR20190121315A (ko) 2017-03-01 2019-10-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 병용 요법
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
HUE061607T2 (hu) 2017-10-18 2023-07-28 Jubilant Epipad LLC Imidazopiridin vegyületek mint PAD inhibitorok
CA3080677A1 (en) 2017-11-06 2019-05-09 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
EP3704120B1 (en) 2017-11-24 2024-03-06 Jubilant Episcribe LLC Heterocyclic compounds as prmt5 inhibitors
AU2019234185A1 (en) 2018-03-13 2020-10-01 Jubilant Prodel LLC. Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
TW202124379A (zh) 2019-09-10 2021-07-01 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的５，６－雜芳族化合物
BR112022003799A2 (pt) 2019-09-13 2022-05-24 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
US20220396586A1 (en) * 2019-09-26 2022-12-15 The Global Alliance For Tb Drug Development, Inc. Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections
BR112022005449A2 (pt) 2019-09-30 2022-06-21 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
WO2021063914A1 (en) 2019-09-30 2021-04-08 Janssen Sciences Ireland Unlimited Company 4-quinolinone antibacterial compounds
KR20230157400A (ko) 2021-03-16 2023-11-16 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항박테리아성 화합물
JP2024509997A (ja) 2021-03-17 2024-03-05 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌化合物
JP2024509998A (ja) 2021-03-17 2024-03-05 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌化合物
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
AR127483A1 (es) 2021-10-28 2024-01-31 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10508844A (ja) 1994-11-15 1998-09-02 ファルマシア・アンド・アップジョン・カンパニー 二環式オキサジンおよびチアジンオキサゾリジノン抗菌剤
EP0828741B1 (en) * 1995-05-11 2001-08-29 PHARMACIA & UPJOHN COMPANY Spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones
BRPI0312927B8 (pt) 2002-07-25 2021-05-25 Janssen Pharmaceutica Nv "compostos, derivados de quinolina, composição, seu uso como inibidores micobacteriais, bem como processo para preparação dos referidos derivados".
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
MA27360A1 (fr) 2004-11-23 2005-06-01 Brahim Bennani Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux
CA2672960A1 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
TW200901969A (en) 2007-06-06 2009-01-16 Smithkline Beecham Corp Chemical compounds
TWI498115B (zh) 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
US7666864B2 (en) 2008-03-26 2010-02-23 Global Alliance For Tb Drug Development Bicyclic nitroimidazole-substituted phenyl oxazolidinones
EP2353008A2 (en) 2008-09-22 2011-08-10 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
CA2748274A1 (en) 2008-12-30 2010-07-08 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as raf kinase inhibitors
RU2608611C2 (ru) 2009-11-05 2017-01-23 Юниверсити Оф Нотр Дам Дю Лак СОЕДИНЕНИЯ ИМИДАЗО[1,2-а] ПИРИДИНА, ИХ СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ
CA2793086C (en) * 2010-03-18 2018-08-21 Institut Pasteur Korea Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
PL2751104T3 (pl) 2011-09-01 2020-04-30 Novartis Ag Związki i kompozycje jako inhibitory kinazy c-kit
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
PT2820008T (pt) 2012-03-02 2017-05-05 Genentech Inc Amidas amido-espirocíclicas e derivados de sulfonamidas
KR101918469B1 (ko) 2012-06-04 2018-11-15 한국화학연구원 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
JP6483610B2 (ja) * 2012-07-18 2019-03-13 ユニバーシティ オブ ノートルダム デュ ラック ５，５−ヘテロ芳香族抗感染症化合物
WO2014023814A1 (en) * 2012-08-10 2014-02-13 Janssen R&D Ireland New antibacterial compounds
KR101650716B1 (ko) 2012-11-22 2016-08-24 한국화학연구원 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물
ES2883565T3 (es) 2013-08-02 2021-12-09 Pasteur Institut Korea Compuestos antiinfecciosos
KR101564425B1 (ko) 2013-11-26 2015-10-30 한국화학연구원 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물
CN105524058B (zh) * 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
JP2017533220A (ja) 2014-11-03 2017-11-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 結核処置のための多剤療法
EP3316969B1 (en) 2015-07-02 2022-03-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
EP3472158A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
JP2019518050A (ja) 2016-06-16 2019-06-27 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌薬としての複素環式化合物
KR20190121315A (ko) 2017-03-01 2019-10-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 병용 요법

Also Published As

Publication number Publication date
AU2017286368A1 (en) 2018-12-06
WO2017216281A1 (en) 2017-12-21
CN109476657A (zh) 2019-03-15
EP3472158A1 (en) 2019-04-24
JP2019518046A (ja) 2019-06-27
CA3026010A1 (en) 2017-12-21
EA201990043A1 (ru) 2019-05-31
MA45377A (fr) 2019-04-24
MX2018015656A (es) 2019-03-14
US20190134046A1 (en) 2019-05-09
US11179396B2 (en) 2021-11-23
AU2017286368B2 (en) 2021-02-25
KR20190017948A (ko) 2019-02-20

Similar Documents

Publication Publication Date Title
BR112018076126A2 (pt) compostos heterocíclicos como antibacterianos
BR112017028318A2 (pt) compostos antibacterianos
BR112018075939A2 (pt) compostos heterocíclicos como antibacterianos
BR112017027414A2 (pt) Derivados hidroxiéster, processo para prepará- los e composições farmacêuticas os contendo
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
BR112018014536A2 (pt) derivados de amônio, um processo para sua preparação e composições farmacêuticas contendo os mesmos
BR112017007636A2 (pt) métodos para a preparação de ribosídeos
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
BR112022003799A2 (pt) Compostos antibacterianos
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
BR112017000821A2 (pt) novos compostos de pirimidina substituída.
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
BR112019024566A2 (pt) inibidores de pirazol magl
BR112017008481A2 (pt) composto antimicótico
BR112017019750A2 (pt) processo para preparação de uma forma cristalina de menaquinol, forma cristalina de menaquinol, processo para preparação de uma forma sólida do menaquinol, composição farmacêutica ou nutracêutica e uso da forma cristalina de menaquinol
BR112018011562A2 (pt) novos derivados de fenil
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
BR112019005886A2 (pt) tratamento com água de material lipídico
BR112016013946A8 (pt) quinazolin-thf-aminas como inibidores de pde1, composição farmacêutica que os compreende, processo para preparação da referida composição farmacêutica, bem como uso dos composto e kit
BR112017012930A2 (pt) derivados de imidazopiridazina como inibidores de pi3kbeta.
CL2015003752A1 (es) Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
BR112017013031A2 (pt) derivados de imidazopiridazina ligados à heterociclila como inibidores de pi3kbeta
BR112023018655A2 (pt) Compostos antibacterianos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements